Y. Matsumoto

Concentration-EEG effect relationship of propofol in rats.

S. Dutta, Y. Matsumoto, N. U. Gothgen, 1997, Journal of pharmaceutical sciences.

Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies?

W F Ebling, S. Dutta, Y. Matsumoto, 1996, Journal of pharmaceutical sciences.

Application of Physiologically Based Pharmacokinetic Modeling to Predict Pharmacokinetics in Healthy Japanese Subjects

Y. Matsumoto, C. Gibson, Tamara D. Cabalu, 2018, Clinical pharmacology and therapeutics.

Steady-state propofol brain:plasma and brain:blood partition coefficients and the effect-site equilibration paradox.

S. Dutta, Y. Matsumoto, W. Ebling, 1998, British journal of anaesthesia.

Prevention of bone loss in ovariectomized rats by pulsatile transdermal iontophoretic administration of human PTH(1-34).

Y. Matsumoto, K. Iga, T. Fukuda, 2002, Journal of pharmaceutical sciences.

Propofol pharmacokinetics and pharmacodynamics assessed from a cremophor EL formulation.

W F Ebling, Y. Matsumoto, W. Ebling, 1997, Journal of pharmaceutical sciences.

Pharmacological action and clinical results of Omarigliptin (MARIZEV® tablet), a novel dipeptidyl peptidase-4 inhibitor for once-weekly treatment of Type 2 diabetes.

Y. Matsumoto, T. Okamoto, Yuka Ito, 2017, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

Iontophoretic pulsatile transdermal delivery of human parathyroid hormone (1–34)

Y. Matsumoto, K. Iga, N. Higo, 2001, The Journal of pharmacy and pharmacology.